Elizabet Shvets supports clients in commercializing cell and gene therapies (CGTs) by providing guidance on coding, coverage, and reimbursement approaches.
She also leverages insights from claims-based analyses to support clients in assessing reimbursement rates, target patient demographics, patient location relative to treatment sites, and overall costs throughout CGT journey. Claims-based projects include NTAP, cost-to-charge ratio, patient journey, and treatment network analyses. Elizabet also provides guidance on the unique operational, financial, competitive, and distribution considerations associated with cell and gene therapies and helps clients consider how these elements can impact launch. Elizabet also provided end-to-end support for a gene therapy manufacturer for several years, throughout her time at Avalere until expected launch. This included assessing competitor dynamics and scenario planning, value message building, reimbursement and coding roadmap development, coverage assessment, and development of strategic recommendations for executive level stakeholders.
Prior to joining Avalere, Elizabet worked as a research assistant at the Hunter College Economics Department where she conducted empirical and descriptive research to support health economics research, including the impact of vertical integration on medical malpractice. Additionally, she completed an internship in the Policy and Research Department at PhRMA where she analyzed the drug policy landscape and conducted research to support advocacy efforts around cell and gene therapies and the 340B program. Elizabet is a PhD Candidate in health policy at the George Washington University. She also received a BA and MA in economics from Hunter College and minored in mathematics.